AGP
BBIO icon

Artia Global Partners’s BridgeBio Pharma BBIO Stock Holding History

Artia Global Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Hold
20,400
– – 0.3% 40
2025
Q4 		$1.56M Hold
20,400
– – 0.22% 42
2025
Q3 		$1.06M Buy
+20,400
New +$995K 0.17% 43

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artia Global Partners's BBIO Position: Q1 2026 in Review

Artia Global Partners held its BridgeBio Pharma (BBIO) position steady in Q1 2026 at 20,400 shares worth $1.51M. The position accounts for 0.3% of the portfolio, ranked #40.

Artia Global Partners first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.56M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Artia Global Partners held 20,400 shares of BridgeBio Pharma worth $1.51M as of Q1 2026.
  • Artia Global Partners left its BridgeBio Pharma share count unchanged in Q1 2026.
  • BridgeBio Pharma made up 0.3% of Artia Global Partners's portfolio in Q1 2026, its #40 holding.
  • Artia Global Partners first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • Artia Global Partners's BridgeBio Pharma position peaked at $1.56M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.